Search results
Results from the WOW.Com Content Network
Assuming the company with better sales of weight loss drugs experiences more growth in its stock price as a result, Evaluate's prediction suggests that Novo Nordisk will be the better pick.
That's why my prediction is that this big oncology bet will help Pfizer stock take off in 2025 -- and that means now is a great time to add this pharmaceutical player to your portfolio.
The stock fell by around 20% on the news in what looked to be a gross overreaction about what may still be the top weight loss drug in the future. ... I predict Summit will have a blockbuster drug ...
Right now, the company's primary sources of growth stem from its GLP-1 drugs Mounjaro and Zepbound, as well as its cancer drug Verzenio -- which received an expanded indication from the FDA last year.
The safest way to benefit from the coming longevity-drug boom will be to invest toward the very end, when the winners are clear, and the remaining growth is set to come from incremental ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Stock market growth in 2025 will extend beyond the Magnificent Seven For the past two years, the group of megacap tech stocks dubbed the Magnificent Seven powered U.S. equities to their historic ...
Eli Lilly's stock has risen 53% so far this year due to the incredible success of these products. However, the company is currently developing another drug that could send the stock price even higher.